| Title |
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, May 2015
|
| DOI | 10.1007/s00262-015-1703-7 |
| Pubmed ID | |
| Authors |
Katy J. McCann, Rosemary Godeseth, Lindsey Chudley, Ann Mander, Gianfranco Di Genova, Paul Lloyd-Evans, Jonathan P. Kerr, Vladimir B. Malykh, Matthew W. Jenner, Kim H. Orchard, Freda K. Stevenson, Christian H. Ottensmeier |
| Abstract |
We report on the safety and immunogenicity of idiotypic DNA vaccination in a phase I, non-randomised, open-label study in patients with multiple myeloma. The study used DNA fusion gene vaccines encoding patient-specific single chain variable fragment, or idiotype (Id), linked to fragment C (FrC) of tetanus toxin. Patients in complete or partial response following high-dose chemotherapy and autologous stem cell transplant were vaccinated intramuscularly with 1 mg DNA on six occasions, beginning at least 6 months post-transplant; follow-up was to week 52. Fourteen patients were enrolled on study and completed vaccinations. Idiotypic DNA vaccines were well tolerated with vaccine-related adverse events limited to low-grade constitutional symptoms. FrC- and Id-specific T-cell responses were detected by ex vivo ELISPOT in 9/14 and 3/14 patients, respectively. A boost of pre-existing anti-FrC antibody (Ab) was detected by ELISA in 8/14 patients, whilst anti-Id Ab was generated in 1/13 patients. Overall, four patients (29 %) made an immune response to FrC and Id, with six patients (43 %) responding to FrC alone. Over the 52-week study period, serum paraprotein was undetectable, decreased or remained stable for ten patients (71 %), whilst ongoing CR/PR was maintained for 11 patients (79 %). The median time to progression was 38.0 months for 13/14 patients. Overall survival was 64 % after a median follow-up of 85.6 months. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Turkey | 1 | 2% |
| Belgium | 1 | 2% |
| Unknown | 50 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 12% |
| Researcher | 6 | 12% |
| Student > Master | 6 | 12% |
| Student > Bachelor | 5 | 10% |
| Other | 4 | 8% |
| Other | 13 | 25% |
| Unknown | 12 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 42% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Agricultural and Biological Sciences | 4 | 8% |
| Immunology and Microbiology | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 14 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2015.
All research outputs
#20,941,392
of 23,577,654 outputs
Outputs from Cancer Immunology, Immunotherapy
#2,652
of 2,948 outputs
Outputs of similar age
#224,042
of 266,741 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#32
of 44 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,948 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,741 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.